

## **Dorset Medicines Advisory Group (DMAG) Annual Report for 2018/2019**

### **1. Introduction**

#### **Background**

- 1.1. The Dorset Medicines Advisory Group (DMAG) is a stakeholder group for the health community to ensure sound local decision making about medicines. It's structure and function is consistent with the NICE recommendations for developing and updating local formularies within <https://www.nice.org.uk/guidance/mpg1>.
- 1.2. The Group has reported directly to the Clinical Commissioning Committee Chairs (CCC). The Group work programme is delivered by its existing working groups or specific task and finish groups to ensure timely, consistent and robust review. Where possible the work programmes are aligned with the workstreams of the elective care programmes.
- 1.3. The Group also supports Public Health Dorset to take account of medicines implications in delivery of their priorities to ensure consistency across the health community.
- 1.4. Provider Trusts, as stakeholders, contribute to the agenda of the Group and the DMAG receives input from the local drug and therapeutics committees (D&Ts).
- 1.5. Regional Medicines Optimisation Committees have been establishing themselves in this financial year and the work programme of DMAG and it's working groups are aligned with the RMOC workplan.

### **2. The purpose and aims of the Group**

- 2.1. DMAG assumes the responsibility for promoting cost-effective, rational use of medicines across the Dorset health community by:
  - Horizon scanning, advising and supporting clinical commissioning decisions on the introduction of new drugs in the local health community, ensuring a consistent approach across the county;
  - Supporting the inclusion of drugs recommended through NICE Technology Appraisals on the Dorset formulary, and identification of any commissioning issues related to the inclusion of such drugs;

- Allocation of a 'traffic light status' for individual drugs ;
- Ongoing maintenance, implementation, review and updating of the Dorset formulary;
- Development of local clinical guidelines and shared care guidelines for drugs with an 'amber' shared care traffic light status;
- Input into elective care or service delivery programmes within the CCG with regard to pharmaceutical interventions and recommendations on their place in relevant treatment pathway.

### **3. Membership**

3.1. Membership of DMAG currently comprises a wide variety of professional, clinical, commissioning, managerial, and organisational backgrounds, and comprises the following attendees:

- NHS Provider organisations (x4):
  - Trust drug and therapeutics chair;
  - Chief Pharmacist.
- NHS Dorset CCG:
  - CCG prescribing lead (Chair from March 2015);
  - Locality GP prescribing lead (1 from each cluster);
  - Chief Pharmacist;
  - Senior Pharmacists (includes NICE associate);
- Service Delivery representative;
- Patient and public representative;
- Local Authority Public Health representative;
- RMOC representative (provides input).

### **4. Attendance at DMAG meetings**

- 4.1. The Group meets bi-monthly. There were six meetings in the 2018/19 financial year.
- 4.2. The CCG has been represented at every meeting. Implementation of videoconferencing between Canford and Vespasian House has improved the ability of Trust representatives to attend. Members of the group are encouraged that where they are unable to attend a nominated deputy attends.

### **5. Drugs classified under the Traffic Light System in 2018/2019**

- 5.1. [Appendix 1](#) contains a summary table of all the drugs allocated a traffic light between April 2018 and March 2019.

## **6. Guidance ratified**

- 6.1. [Appendix 2](#) contains a summary table of all the guidance ratified by DMAG between April 2018 and March 2019 and a list of other amendments made to the formulary and/or existing guidance.

## **7. NICE Technology Appraisals**

- 7.1. All NICE technology appraisals which are the responsibility of the CCG are considered through the DMAG. This totaled 6 technology appraisals in 2018/2019.
- 7.2. The CCG has ensured that funding is available for all drugs approved for use by the NICE TA process within the required 90-day statutory period (30 days for 'fast track' appraisals). Where necessary relevant service leads within the CCG have worked alongside DMAG representatives and relevant provider Trusts to facilitate the implementation of the NICE TA drugs within a new or existing service.

## **8. NICE Evidence summaries and Clinical Guidelines**

- 8.1. DMAG and its working groups use relevant evidence summaries and clinical guidelines in their development of new pathways involving medicines and evaluations of new and existing drugs.
- 8.2. One of the NICE associates for Dorset inputs into the DMAG.

## **9. Other topics**

### **Dorset formulary website and app**

- 9.1. The Dorset formulary has been recently recommissioned on its own dedicated website. At the same time, it was decided not to continue funding the app. The collaborative working continues through the formulary working group to manage the site and its content including an ongoing programme of review.

### **Drug safety information**

- 9.2. The DMAG retained a standing item on its agenda to consider safety notices for medicines for most of the last year. The main source of this information is the Medicines and Healthcare Regulatory Agency drug alerts and recalls as well as the Drug Safety Update, along with Central Alerting System (CAS) outputs e.g. patient safety alerts. Safety alerts from the European Medicines Agency (EMA) are also considered. Safety messages may also be highlighted by DMAG working groups and local, regional and national medicines safety officer networks. Examples of safety information acted on in 2018/19 include:
- The progressive update to the warnings on sodium valproate use in females of child-bearing age

- The safety warnings on liver function for Esmya® (ulipristal acetate) for uterine fibroids
- Braltus® - and the risk of inhalation of the whole capsule if placed in the wrong part of the inhaler
- Fentanyl patches - there continues to be reports of unintentional opioid toxicity and overdose of fentanyl due to accidental exposure to patches.
- Emollients - Warnings about the risk of severe and fatal burns are being extended to all paraffin-based emollients regardless of paraffin concentration
- Potassium permanganate formulary status, following cases of accidental ingestion
- Methotrexate 10 mg tablets All prescribers are reminded that oral methotrexate should be prescribed in multiples of 2.5 mg tablets as a once-weekly dose.

From March 2019 the MSO will continue to report to the system-wide Medicines optimization transformation group (MOTG) and the CCG's medicines optimisation group (MOG)

## **10. Recommendation**

- 10.1. Dorset Medicines Advisory Group continues to function as the area prescribing committee to bring together clinical decision making and promote the cost-effective use of medicines across the health economy. All organisations remain committed to it.
- 10.2. The terms of reference and reporting structure of DMAG is being reviewed for implementation in 2019/20.
- 10.3. The group are asked to note this report.

## Appendix 1: Drugs classified under the Traffic Light System in 2018/2019

DMAG Meeting	Red	Amber	Green	Not recommended	Not formulary
May 2018	<p>Praziquantel (local microbiologists must use FP10HP)</p> <p>Brodalumab for Psoriasis</p> <p>Guselkumab for Psoriasis</p>	<p>Rasagiline (remains amber with shared care but now equal first line option)</p>	<p>Topical diltiazem (second line to topical GTN) anal fissures</p> <p>Soluble analgesics (second line for patients with genuine swallowing difficulties)</p> <p>Medi-Test Glucose Test strips</p> <p>Praziquantel (GP may prescribe on advice of tertiary centre outside Dorset)</p>		<p>Vitamin BPC capsules</p> <p>Piroxicam (all formulations)</p> <p>Cough mixtures</p> <p>Rubefacients</p> <p>Clinistix (discontinued)</p> <p>Strontium (discontinued)</p> <p>Pergolide (Parkinson's disease)</p> <p>Opicapone</p> <p>Ferric Maltol</p> <p>Cabergoline (Parkinson's disease)</p>
July 2018	<p>Vitamin B compound strong</p> <p>Lacosamide, perampanel and zonisamide</p> <p>Promethazine</p> <p>Dupilumab</p>	<p>Pilocarpine tablets (Salagen®)</p> <p>Oxcarbazepine</p> <p>Emollient bath and shower preparations</p>	<p>Amitriptyline for Depression</p> <p>Symbicort® MDI</p> <p>Aerochamber Plus Flo-Vu</p> <p>Pramipexole and ropinirole (low dose)</p>	<p>Zafirlukast (Discontinued)</p>	<p>Vitamin B compound</p> <p>Oxazepam</p> <p>Eslicarbazepine</p> <p>Loxapine</p> <p>Brivaracetam</p>

DMAG Meeting	Red	Amber	Green	Not recommended	Not formulary
<p>July 18 Formulary amendments made in line with NHS England” Guidance on conditions for which over the counter items should not routinely be prescribed in primary care.</p>	<p>Peppermint water</p>		<p>Exorex® (Restricted) Capasal® (Restricted) Ceanel® (Restricted) Nizoral® (Restricted) Selsun® (Restricted) Aluminium chloride antiperspirants (Restricted) Benzoyl peroxide preparation (Green, for use within acne guideline when required in combination with antibiotics) Emollients for mild dry skin (Advise purchase when part of routine skin care in the absence of a moderate to severe skin conditions) Sunscreens within ACBS criteria for Anthelios®, Sensense® and Uvistat® only Dermacool® - Restricted to pruritic conditions where moderate to severe skin condition require it.</p>		<p>Peppermint oil caps Eurax®/Eurax® HC Dentinox® cradle cap shampoo Probiotics</p>

DMAG Meeting	Red	Amber	Green	Not recommended	Not formulary
September 2018	<p>Freestyle Libre for paediatric patients - Red for initial six months progressing to amber if positive patient outcomes.</p> <p>Injectable antibiotic, ceftazidime-avibactam.</p> <p>Ixekizumab for psoriatic arthritis (In accordance with local pathway)</p> <p>Silver nitrate</p> <p>Xylometazoline</p> <p>Oclusal®, Salactol®, (used at DCH)</p> <p>Glutarol®, Verrugon® solutions (used at RBH)</p> <p>Olive Oil</p> <p>AA enema</p> <p>Potassium citrate</p> <p>Adcortyl in Orabase®</p> <p>Bonjela</p>	<p>Trehalose 3%, Sodium Levofloxacin eye drops and moxifloxacin eye drops</p> <p>Hyaluronate 0.15% drops, and with Carbomer 0.25% for gel. (Thealoz Duo®)</p> <p>Alfacalcidol (Remains Amber but with SCG)</p> <p>Lisdexamfetamine (Elvanse Adult®) Amber with shared care</p> <p>Mepitel® dressings</p> <p>Abidec® and Sytron® (with comment to be initiated only in Secondary care)</p>	<p>Bismuth subsalicylate tablets</p> <p>K-Three® system (multi-layer compression)</p> <p>Headlice products (second line)</p>	<p>Fluphenazine Decanoate (Modecate®)-Discontinued</p>	<p>Tioconazole</p> <p>Co-phenotrope (Discontinued)</p> <p>Zetuvit E® (non sterile) and Zetuvit® (sterile)</p> <p>Liraglutide (Saxenda®)</p> <p>Coughs and colds: Benz co., benz tincture</p> <p>Chlorhexidine/ tetracain</p> <p>Docusate sodium ear drops 0.5%</p> <p>Waxsol®</p> <p>Pregaday®</p> <p>Sudocrem®</p> <p>Metanium®</p>

DMAG Meeting	Red	Amber	Green	Not recommended	Not formulary
November 2018	Tofacitinib <a href="#">NICETA 543</a>		<p>Ofloxacin Azithromycin liquid</p> <p>Calcium-Sodium Alginate fibre dressings (Kaltostat®) 5x5cm, 7.5x12cm, 10x20cm 15x25cm</p> <p>KerraCel® Gelling Fiber Dressing “All sizes” to be added to the formulary entry.</p>		<p>Fentanyl reservoir patches Dapagliflozin/ saxagliptin (Qtern®) Brivaracetam</p>
January 2019	<p>Lidocaine plaster (Only within licensed indication (post herpetic neuralgia). It remains non-formulary for other indications.) Minocycline (oral) Tofacitinib <a href="#">NICETA 547</a></p>	<p>Opicapone with SCG Lacosamide with SCG Zonisamide with SCG Nadolol with SCG Bath/shower emollients (Except for Dermol 600®)</p>	<p>Frovatriptan Rizatriptan Buprenorphine patches (5mcg/hr, 10mcg/hr and 20mcg patches)</p> <p>Only for patients with genuine swallowing difficulties who don't require a daily morphine dose exceeding 60mg.)</p> <p>Dequalinium chloride 10mg vaginal tablets (Fluomizin®) Cetamacrogol A cream</p>		<p>Almotriptan Tolcapone Oilatum Plus</p>



DMAG Meeting	Red	Amber	Green	Not recommended	Not formulary
March 2019	Anti-malarials Dundee sunscreen® (No Longer ACBS) Heparinised saline Zanamivir (intravenous) Faecal microbiota transfer (FMT) Hexvix®	Perampanel with SCG Tiagabine with SCG Alkindi® (hydrocortisone granules) with SCG	Microdot Verifine 5mm/30g safety needle		Symprove®

## Appendix 2: Guidance ratified by DMAG in 2018/2019

DMAG meeting	Type of guidance			
	Shared care guidance	Clinical guidance/pathway	Commissioning statement	Other guidance
May 2018	<p>Shared Care Guideline for amantadine</p> <p>Shared Care Guideline for dopamine agonists (non-ergot derived)</p> <p>Shared Care Guidelines for prescribing entacapone</p> <p>Shared Care Guidelines selegiline and rasagiline</p> <p>Shared Care Guideline for prescribing denosumab (Prolia®)</p> <p>Shared Care Guideline for the use of Oral Ibandronic Acid in early Breast Cancer.</p>	<p>Dorset COPD guideline</p> <p>Local guideline 'Pharmacological management of Parkinson's disease'</p> <p>Primary and Secondary Prevention: Medical Management of men and women who have (or are at risk of) Osteoporosis'</p> <p>The management of psoriasis in adults</p> <p>Policy statement – Management of hyperhidrosis. updated pathway</p> <p>Pan Dorset Wound Care Formulary – treat according to highest percentage of tissue type</p>	<p>Commissioning statement on the use of brodalumab for treating moderate to severe plaque psoriasis in response to NICE TA511</p>	<p>Schematic diagram for DMAG</p> <p>Statement regarding prescribing of sterile dressing packs in primary care'.</p> <p>Guideline to support prescribing calcitonin in acute bone loss due to sudden immobilization.</p> <p>Guidelines for the prescribing of Stoma Additional Products Preferred in Primary Care</p> <p>Prescribing across the interface</p> <p>Wessex infant feeding guidelines</p> <p>Anti-microbial product information for the treatment of Infected/critically colonised wounds</p>
July 2018	<p>Updated shared care guideline for the use of buccal midazolam in adults</p> <p>Updated shared care guidelines for Entresto® added to the formulary.</p>	<p>Updated and amended Policy for "Stopping DOACs before procedure.</p>		<p>NHS England "Guidance on conditions for which over the counter items should not routinely be prescribed in primary care"</p>
September 2018	<p>Revised shared care guideline for cinacalcet</p> <p>Shared care guideline for denosumab</p>		<p>Statement to support the non-formulary status of liraglutide (as brand Saxenda®) for weight loss</p>	<p>NHS England "Guidance on conditions for which over the counter items should not routinely be prescribed in primary care"</p>

DMAG meeting	Type of guidance			
	Shared care guidance	Clinical guidance/pathway	Commissioning statement	Other guidance
	Shared care guideline and commissioning statement for brimonidine		Commissioning statement for Omalizumab for previously treated chronic spontaneous urticaria Commissioning statement for Pigmanorm®	Shared care guideline for calcitonin Guideline for the primary and secondary prevention of osteoporosis Guideline for prescribing eflornithine (Vaniqa®) for facial hirsutism
November 2018	Updated NICE TA 217 for prescribing in Alzheimer's Disease and other dementia updated to reflect new recommendations - SCG for drugs for dementia SCG for drugs used in ADHD			Dorset Opioid Resource Pack Formulary schematic diagram Prescribing guideline for tacrolimus  RMOC Insulin Preparations: Safety Factors for Local Formulary Decision-Making Position Statement and associated checklist Pan Dorset antifungal policy - approved for use in Trusts (will be approved at the joint RBH and PFT D&T committee)
January 2019	Shared care guideline for entacapone and opicapone Shared care guideline for zonisamide		Cannabis commissioning statement	Guidance on infective endocarditis RBCH DOAC checklist

DMAG meeting	Type of guidance			
	Shared care guidance	Clinical guidance/pathway	Commissioning statement	Other guidance
	Shared care guideline for lacosamide Shared care guideline for nadolol			
March 2019	Shared care guideline for use of hydrocortisone granules (Alkindi®) in adrenal insufficiency in children Shared care guideline for GLP-1s Shared care guideline for the use of topical tacrolimus and pimecrolimus for the treatment of atopic eczema Shared care guideline for liothyronine	Trans-anal irrigation pathway Psoriasis pathway	GLP-1 commissioning statement Commissioning statement for Dundee sunscreen	Vitamin D guidelines Urinary management preferred product list Bowel continence formulary

Other amendments to the formulary during 2018/2019:

Entry for Normasol® to be amended to the generic sodium chloride 0.9%.

Dressing packs – Nurse-It® to be added to formulary as the brand available on FP10. A reminder on the guidance on the use of sterile dressing packs to be added to the entry.

Sticker and leaflet produced to reduce telephone calls from care homes for inappropriate treatment of UTIs to be made available on the formulary

Suprasorb® X+PHMB Dressing Further prescribing information added to formulary entry “appropriate secondary dressings are C-View® (film) or Biatain® Silicone (foam) depending on the exudate level, location and skin state”

**NICE TAs:**

[NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis](#)

[NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis](#)

[NICE TA 543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs](#)

[NICE TA 547 Tofacitinib for moderately to severely active ulcerative colitis](#)

[NICE TA534 Fast Track appraisal Dupilumab](#)

[NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs](#)